DGIdb - PANOBINOSTAT Drug Record

PANOBINOSTAT chembl:CHEMBL483254 ApprovedAntineoplasticImmunotherapy

Alternate Names:

PANOBINOSTAT
FARYDAK
LBH589
LBH-589
LBH 589
FARYDAK®
(2E)-N-HYDROXY-3-[4-({[2-(2-METHYL-1H-INDOL-3-YL)ETHYL]AMINO}METHYL)PHENYL]ACRYLAMIDE
pubchem.compound:6918837
chemidplus:404950-80-7
chembl:CHEMBL483254
drugbank:06603
rxcui:1603350

Drug Info:

FDA Approval	Multiple myeloma
Drug Class	Small molecule inhibitor
FDA Approval	not approved
Drug Class	small molecule
Drug Indications	antineoplastic agent
Pharmaceutical Developer	Novartis
Source Reported Drug Name(s)	Panobinostat
Drug Class	HDAC Inhibitor

(5 More Sources)

Publications:

Li X et al., 2014, Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity., J Med Chem
Beckers et al., 2007, Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group., Int. J. Cancer
Geng et al., 2006, Histone deacetylase (HDAC) inhibitor LBH589 increases duration of gamma-H2AX foci and confines HDAC4 to the cytoplasm in irradiated non-small cell lung cancer., Cancer Res.
Hayes et al., 2016, Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression., Cancer Cell
Qian et al., 2012, Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling., Clin. Cancer Res.
Scholl et al., 2009, Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells., Cell
Cruickshank et al., 2017, Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin., Leukemia
LaBonte et al., 2011, The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models., Cancer Res.
Landreville et al., 2012, Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma., Clin. Cancer Res.
Muscat et al., 2016, Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumor Growth Arrest and Multi-Lineage Differentiation of Malignant Rhabdoid Tumors., Clin. Cancer Res.
Shahbazi J et al., 2016, The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects., Clin Cancer Res

PANOBINOSTAT BAP1

Interaction Score: 1.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22038994

Sources:
CIViC
PANOBINOSTAT SMARCB1

Interaction Score: 1.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26920892

Sources:
CIViC
PANOBINOSTAT MYCN

Interaction Score: 0.81

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26733615

Sources:
CIViC
PANOBINOSTAT HDAC1

Interaction Score: 0.7

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Reported Cancer Type Prostate

Trial Name Panobinostat

PMIDs:
24694055 17455259 17145876

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial CancerCommons TTD
PANOBINOSTAT HDAC3

Interaction Score: 0.38

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Panobinostat

Novel drug target Established target

Notes

PMIDs:
24694055

Sources:
TALC DTC TdgClinicalTrial
PANOBINOSTAT HDAC6

Interaction Score: 0.37

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name Panobinostat

Novel drug target Established target

PMIDs:
24694055

Sources:
TALC DTC TdgClinicalTrial
PANOBINOSTAT HDAC2

Interaction Score: 0.37

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name Panobinostat

Notes

PMIDs:
24694055

Sources:
TALC DTC TdgClinicalTrial
PANOBINOSTAT HDAC9

Interaction Score: 0.34

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Panobinostat

Novel drug target Established target

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial
PANOBINOSTAT HDAC7

Interaction Score: 0.31

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Panobinostat

Novel drug target Established target

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial
PANOBINOSTAT HDAC4

Interaction Score: 0.28

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name Panobinostat

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial
PANOBINOSTAT HDAC11

Interaction Score: 0.24

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name Panobinostat

Notes

PMIDs:
None found

Sources:
TALC TdgClinicalTrial
PANOBINOSTAT HDAC10

Interaction Score: 0.22

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Panobinostat

Novel drug target Established target

Notes

PMIDs:
None found

Sources:
TALC TdgClinicalTrial
PANOBINOSTAT HDAC5

Interaction Score: 0.21

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name Panobinostat

Novel drug target Established target

PMIDs:
None found

Sources:
TALC TdgClinicalTrial
PANOBINOSTAT HDAC8

Interaction Score: 0.2

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name Panobinostat

Novel drug target Established target

PMIDs:
None found

Sources:
TALC TdgClinicalTrial
PANOBINOSTAT KMT2A

Interaction Score: 0.15

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
27443263

Sources:
JAX-CKB
PANOBINOSTAT KRAS

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

Approval Status Preclinical - Cell culture

Indication/Tumor Type pancreatic ductal adenocarcinoma

combination therapy Panobinostat + SCH772984

PMIDs:
26725216 22693356 19490892

Sources:
JAX-CKB
PANOBINOSTAT BRAF

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Lapatinib + Panobinostat

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
21464044

Sources:
JAX-CKB

MyCancerGenome: PANOBINOSTAT
- Version: 20-Jun-2017
Alternate Names:

FARYDAK Trade Name

Drug Info:

Drug Class Small molecule inhibitor

FDA Approval Multiple myeloma

Publications:
CancerCommons: PANOBINOSTAT
- Version: 25-July-2013
Alternate Names:

Panobinostat PubChem Drug Name

6918837 PubChem Drug ID

Panobinostat Drug Trade Name

Drug Info:

Drug Class HDAC Inhibitor

Source Reported Drug Name(s) Panobinostat

Pharmaceutical Developer Novartis

Publications:
TdgClinicalTrial: PANOBINOSTAT
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications antineoplastic agent

Drug Class small molecule

FDA Approval not approved

Publications:
DTC: PANOBINOSTAT
- Version: 02-September-2020
Alternate Names:

CHEMBL483254 ChEMBL Drug ID

Drug Info:

Publications:

Li X et al., 2014, Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity., J Med Chem

JAX-CKB: Panobinostat

Version: 27-September-2017

Alternate Names:

Drug Info:

Publications:

Qian et al., 2012, Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling., Clin. Cancer Res.

Scholl et al., 2009, Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells., Cell

Hayes et al., 2016, Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression., Cancer Cell

CIViC: PANOBINOSTAT

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Landreville et al., 2012, Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma., Clin. Cancer Res.

Shahbazi J et al., 2016, The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects., Clin Cancer Res

Muscat et al., 2016, Low-Dose Histone Deacetylase Inhibitor Treatment Leads to Tumor Growth Arrest and Multi-Lineage Differentiation of Malignant Rhabdoid Tumors., Clin. Cancer Res.

TALC: PANOBINOSTAT
- Version: 12-May-2016
Alternate Names:

PANOBINOSTAT Primary Drug Name

PANOBINOSTAT Drug Generic Name

FARIDAK Drug Trade Name

Drug Info:

Publications:
TTD: Panobinostat
- Version: 2020.06.01
Alternate Names:

D0E3SH TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL483254
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Trial Name	Panobinostat
Novel drug target	Established target
Notes

Evidence Type	Actionable
Approval Status	Preclinical - Cell culture
Response Type	sensitive

Approval Status	Preclinical - Cell culture
Indication/Tumor Type	pancreatic ductal adenocarcinoma
combination therapy	Panobinostat + SCH772984

combination therapy	Lapatinib + Panobinostat
Indication/Tumor Type	colorectal cancer
Response Type	sensitive

Panobinostat	PubChem Drug Name
6918837	PubChem Drug ID
Panobinostat	Drug Trade Name

PANOBINOSTAT	Primary Drug Name
PANOBINOSTAT	Drug Generic Name
FARIDAK	Drug Trade Name

PANOBINOSTAT Drug Record

PANOBINOSTAT chembl:CHEMBL483254 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22038994

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26920892

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26733615

Sources: CIViC

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Reported Cancer Type Prostate Trial Name Panobinostat

PMIDs: 24694055 17455259 17145876

Sources: TALC DTC MyCancerGenome TdgClinicalTrial CancerCommons TTD

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Panobinostat Novel drug target Established target Notes

PMIDs: 24694055

Sources: TALC DTC TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name Panobinostat Novel drug target Established target

PMIDs: 24694055

Sources: TALC DTC TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name Panobinostat Notes

PMIDs: 24694055

Sources: TALC DTC TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Panobinostat Novel drug target Established target Notes

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Panobinostat Novel drug target Established target Notes

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name Panobinostat Notes

PMIDs: None found

Sources: TALC MyCancerGenome TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name Panobinostat Notes

PMIDs: None found

Sources: TALC TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Trial Name Panobinostat Novel drug target Established target Notes

PMIDs: None found

Sources: TALC TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name Panobinostat Novel drug target Established target

PMIDs: None found

Sources: TALC TdgClinicalTrial

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Notes Trial Name Panobinostat Novel drug target Established target

PMIDs: None found

Sources: TALC TdgClinicalTrial

Interaction Types & Directionality: n/a

Interaction Info: Evidence Type Actionable Approval Status Preclinical - Cell culture Response Type sensitive

PMIDs: 27443263

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: Approval Status Preclinical - Cell culture Indication/Tumor Type pancreatic ductal adenocarcinoma combination therapy Panobinostat + SCH772984

PMIDs: 26725216 22693356 19490892

Sources: JAX-CKB

Interaction Types & Directionality: n/a

Interaction Info: combination therapy Lapatinib + Panobinostat Indication/Tumor Type colorectal cancer Response Type sensitive

PMIDs: 21464044

Sources: JAX-CKB

MyCancerGenome: PANOBINOSTAT

Alternate Names: FARYDAK Trade Name

Drug Info: Drug Class Small molecule inhibitor FDA Approval Multiple myeloma

Publications:

CancerCommons: PANOBINOSTAT

Alternate Names: Panobinostat PubChem Drug Name 6918837 PubChem Drug ID Panobinostat Drug Trade Name

Drug Info: Drug Class HDAC Inhibitor Source Reported Drug Name(s) Panobinostat Pharmaceutical Developer Novartis

Interaction Types & Directionality:

n/a

PMIDs:
22038994

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
26920892

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
26733615

Sources:
CIViC

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Reported Cancer Type Prostate

Trial Name Panobinostat

PMIDs:
24694055 17455259 17145876

Sources:
TALC DTC MyCancerGenome TdgClinicalTrial CancerCommons TTD

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Panobinostat

Novel drug target Established target

Notes

PMIDs:
24694055

Sources:
TALC DTC TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name Panobinostat

Novel drug target Established target

PMIDs:
24694055

Sources:
TALC DTC TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name Panobinostat

Notes

PMIDs:
24694055

Sources:
TALC DTC TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Panobinostat

Novel drug target Established target

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Panobinostat

Novel drug target Established target

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name Panobinostat

Notes

PMIDs:
None found

Sources:
TALC MyCancerGenome TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name Panobinostat

Notes

PMIDs:
None found

Sources:
TALC TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Trial Name Panobinostat

Novel drug target Established target

Notes

PMIDs:
None found

Sources:
TALC TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name Panobinostat

Novel drug target Established target

PMIDs:
None found

Sources:
TALC TdgClinicalTrial

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Notes

Trial Name Panobinostat

Novel drug target Established target

PMIDs:
None found

Sources:
TALC TdgClinicalTrial

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Preclinical - Cell culture

Response Type sensitive

PMIDs:
27443263

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

Approval Status Preclinical - Cell culture

Indication/Tumor Type pancreatic ductal adenocarcinoma

combination therapy Panobinostat + SCH772984

PMIDs:
26725216 22693356 19490892

Sources:
JAX-CKB

Interaction Types & Directionality:

n/a

Interaction Info:

combination therapy Lapatinib + Panobinostat

Indication/Tumor Type colorectal cancer

Response Type sensitive

PMIDs:
21464044

Sources:
JAX-CKB

Alternate Names:

FARYDAK Trade Name

Drug Info:

Drug Class Small molecule inhibitor

FDA Approval Multiple myeloma

Alternate Names:

Panobinostat PubChem Drug Name

6918837 PubChem Drug ID

Panobinostat Drug Trade Name

Drug Info:

Drug Class HDAC Inhibitor

Source Reported Drug Name(s) Panobinostat

Pharmaceutical Developer Novartis

Drug Info:

Drug Indications antineoplastic agent

Drug Class small molecule

FDA Approval not approved

Alternate Names:

CHEMBL483254 ChEMBL Drug ID

Publications:

Li X et al., 2014, Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity., J Med Chem

Alternate Names:

PANOBINOSTAT Primary Drug Name

PANOBINOSTAT Drug Generic Name

FARIDAK Drug Trade Name

Alternate Names:

D0E3SH TTD Drug ID